A Phase 3, 24-Week, Multi-Center, Open-Label, Randomized, Controlled Trial Comparing the Efficacy and Safety of Prandial Inhalation of Technosphere/Insulin in Combination With Metformin or Technosphere/Insulin Alone Versus 2 Oral Anti-Diabetic Agents (Metformin and a Secretagogue) in Subjects With Type 2 Diabetes Mellitus Sub-optimally Controlled on Combination Metformin and a Secretagogue.
A Phase 3, 24-Week, Multi-Center, Open-Label, Randomized, Controlled Trial Comparing the Efficacy and Safety of Prandial Inhalation of Technosphere/Insulin in Combination With Metformin or Technosphere/Insulin Alone Versus 2 Oral Anti-Diabetic Agents (Metformin and a Secretagogue) in Subjects With Type 2 Diabetes Mellitus Sub-optimally Controlled on Combination Metformin and a Secretagogue.
to demonstrate the efficacy of inhaled Technosphere/Insulin in combination with metformin versus combination metformin and a secretagogue
Inclusion Criteria:
Exclusion Criteria:
Mexico City, Durango 06700, Mexico
Bialystock, POL 15-276, Poland
Krakow, POL 31 501, Poland
Lodz, 90-153, Poland
Moscow, RUS 105229, Russia
Moscow, RUS 111399, Russia
Moscow, RUS 115478, Russia
Moscow, RUS 129110, Russia
Saint Petersburg, RUS 193012, Russia
Smolensk, RUS 214018, Russia
Chernivtsy, UKR 58022, Ukraine
Dniepropetrovsk, UKR 49023, Ukraine